Prognostic value of T-1 cell numbers prior to allogeneic stem cell transplantation in patients with severe graft-versus-host disease

[1]  D. Jain,et al.  Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. , 2004, Blood.

[2]  G. Banna,et al.  Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. , 2004, Critical reviews in oncology/hematology.

[3]  R. Chopra,et al.  Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience1 , 2003, Bone Marrow Transplantation.

[4]  B. Yeap,et al.  Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  G. Henze,et al.  Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. , 2003, Blood.

[6]  M. Gilleece,et al.  Donor Lymphocyte Infusions for Patients who Relapse After Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia , 2003, Leukemia & lymphoma.

[7]  J. Barrett.  Allogeneic stem cell transplantation for chronic myeloid leukemia. , 2003, Seminars in hematology.

[8]  J. Sierra,et al.  Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. , 2003, Haematologica.

[9]  U. Banning,et al.  Intracellular detection of T-cell cytokines. Differentiation of TH1 and TH2 cells. , 2003, Methods in molecular biology.

[10]  E. Montserrat,et al.  Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. , 2002, Blood.

[11]  K. Horibe,et al.  Outcome After Relapse in Childhood Acute Lymphoblastic Leukemia , 2002, International journal of hematology.

[12]  M. Brink,et al.  Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C , 2002, Bone Marrow Transplantation.

[13]  H. Inoko,et al.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. , 2002, Blood.

[14]  H. Veelken,et al.  Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Radich,et al.  Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases , 2002, International journal of hematology.

[16]  M. Horowitz,et al.  Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  C Anasetti,et al.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. , 2001, Blood.

[18]  M. Remberger,et al.  Treatment of severe acute graft‐versus‐host disease with anti‐thymocyte globulin , 2001, Clinical transplantation.

[19]  N. Chao,et al.  Acute graft-vs-host disease: pathobiology and management. , 2001, Experimental hematology.

[20]  S. Ikehara,et al.  Differential Regulation of Human Blood Dendritic Cell Subsets by IFNs1 , 2001, The Journal of Immunology.

[21]  B. Blazar,et al.  A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  H. Bönig,et al.  ‘Sepsis’ and multi-organ failure: predictors of poor outcome after hematopoietic stem cell transplantation in children , 2000, Bone Marrow Transplantation.

[23]  W. Wilmanns,et al.  Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation , 2000, Bone Marrow Transplantation.

[24]  H. Bönig,et al.  Monocyte deactivation and its reversal in a patient with chemotherapy-induced leukopenia and severe systemic infection. , 2000, Medical and pediatric oncology.

[25]  S. Davies,et al.  Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. , 1999, Blood.

[26]  R. Westendorp,et al.  Interleukin 10 secretion in relation to human IL-10 locus haplotypes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Burdach,et al.  The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses. , 1997, Blood.

[28]  M. Steinbuch,et al.  ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival , 1997, Annals of Hematology.

[29]  J. Butterfield,et al.  IFN-gamma-stimulated enhancement of MHC class II antigen expression by the human mast cell line HMC-1. , 1996, Cellular immunology.

[30]  W. Gause,et al.  Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. , 1995, Journal of immunology.

[31]  M. Sykes.  Novel approaches to the control of graft versus host disease. , 1993, Current opinion in immunology.

[32]  R. de Waal Malefyt,et al.  Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. , 1992, International immunology.

[33]  H. Tilg,et al.  Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. , 1990, Transplantation.

[34]  D. Niederwieser,et al.  IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. , 1988, Journal of immunology.

[35]  H. Deeg,et al.  Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. , 1985, Transplantation.

[36]  G. Wong,et al.  Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines. , 1983, Journal of immunology.

[37]  R. Storb,et al.  Treatment of graft‐versus‐host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroids , 1981, American journal of hematology.

[38]  R. Storb,et al.  Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. , 1978, Transplantation proceedings.